In patients with cardiovascular disease (CVD), depression is common, persistent, and associated with worse health-related quality of life, recurrent cardiac events, and mortality. Both physiological and behavioral factors—including endothelial dysfunction, platelet abnormalities, inflammation, autonomic nervous system dysfunction, and reduced engagement in health-promoting activities—may link depression with adverse cardiac outcomes. Because of the potential impact of depression on quality of life and cardiac outcomes, the American Heart Association has recommended routine depression screening of all cardiac patients with the 2- and 9-item Patient Health Questionnaires. However, despite the availability of these easy-to-use screening tools and effective treatments, depression is underrecognized and undertreated in patients with CVD. In this paper, we review the literature on epidemiology, phenomenology, comorbid conditions, and risk factors for depression in cardiac disease. We outline the associations between depression and cardiac outcomes, as well as the mechanisms that may mediate these links. Finally, we discuss the evidence for and against routine depression screening in patients with CVD and make specific recommendations for when and how to assess for depression in this high-risk population.

1. Introduction

Depression in cardiac disease is common, persistent, underrecognized, and deadly. Over the past 20 years, research has found that not only is depression more common in cardiac patients than in the general population, but depression is also a risk factor for cardiac morbidity and mortality, independent of traditional risk factors. This link between depression and cardiac morbidity likely involves both physiologic and behavioral effects of depression. Fortunately, screening for depression in cardiac patients is straightforward, and methods of diagnosis essentially parallel those for major depressive disorder (MDD) diagnosis in other settings. In this paper, we will review the epidemiology, course, impact, pathogenesis, and diagnostic assessment of depression in patients with cardiovascular disease (CVD). We will define depression as either elevated depressive symptoms on a validated depression scale or a formal diagnosis of MDD. Of note, we will not specifically address treatment of depression in cardiac patients, a topic that is worthy of its own separate review and that has been recently reviewed in detail [1].

2. Prevalence of Depression in Cardiac Patients

Depression is highly prevalent in cardiac patients. Between 31–45% of patients with coronary artery disease (CAD), including those with stable CAD, unstable angina, or myocardial infarction (MI), suffer from clinically significant depressive symptoms [2]. Furthermore, 15–20% of patients with CAD meet criteria at any given time for the full syndrome of MDD [3–7]; this rate of MDD is roughly threefold higher than in the general population [8] and is similar to the rates of MDD in patients with chronic kidney disease [9] and cancer [10].

Patients with heart failure (HF), atrial fibrillation (AF) and those undergoing implantable cardioverter-defibrillator
(ICD) placement are similarly at increased risk for elevated depressive symptoms and for MDD [11–13]. A meta-analysis of patients with HF found prevalence rates of 36% for increased depressive symptoms and 20% for MDD [12]. Furthermore, a recent systematic review of ICD patients found depressive disorders (e.g., MDD, dysthymic disorder) to be present in 11–28% of patients [11]. Finally, among patients undergoing coronary artery bypass graft (CABG) surgery, approximately 30–40% of patients meet criteria for dysthymia, minor or major depression, with roughly 15% of patients meeting full MDD criteria on diagnostic interview [14].

3. Course of Illness

In patients with CVD, depression is often chronic and recurrent. Among patients with CVD hospitalized for acute cardiac events and found to meet criteria for depression during or shortly after admission, approximately 50–70% had ongoing depressive symptoms that preceded their cardiac event [15–17]; this finding is consistent with literature that describes persistent depression in patients with stable CAD [18]. Furthermore, rather than being a transient reaction to a cardiac event, depression for many patients exists for months or years before and persists long after the event [15–22]. In studies that examine the course of post-MI depression, depressive symptoms remain at steady levels of severity over the 12 months after an MI [19, 20]. Similar results have been observed in patients with chronic CVD, such as those with ICDs; in this cohort, 80% of patients who are depressed at the time of ICD placement continue to suffer from depressive symptoms 2 years later [22]. Finally, among patients admitted with a HF exacerbation and diagnosed with MDD, less than half have a remission of symptoms at 5-month followup [21].

In sum, depression is present in a significant portion of patients across the spectrum of cardiac disease, and such symptoms, when present, are likely to persist unless treated. These findings underscore the need to find better methods for identifying—and managing—depression in patients with CVD.

4. Risk Factors for Depression in Cardiac Patients

Though there are some inconsistencies in the literature, there are several established risk factors for depression in cardiac patients. Most studies have found that younger patients, women, and patients with premorbid histories of depression are more likely to have depression in the context of CVD [25–29]. Among patients suffering from an acute coronary syndrome (ACS), in addition to the previous factors, social isolation, prior ACS, and in some cases, comorbid diabetes may also increase depression risk [27, 28, 30–32].

These factors, as well as poor functional status or worse New York Heart Association (NYHA) HF severity class, have also been linked to depression in patients with HF [33–35]. Among CABG patients, depression pre-CABG is predicted by female gender, younger age, living alone, and less education [36], and post-CABG depression is best predicted, not surprisingly, by pre-CABG depressive symptoms and anxiety [37]. Similarly, among patients with an ICD for ventricular arrhythmias, younger age and female gender predict depression [11]; there is some suggestion, though not definitive evidence, that ICD shocks are linked to higher rates of depression [11, 38].

5. Psychiatric Conditions

Commonly Comorbid with Depression in Cardiac Patients

With respect to comorbid symptoms and conditions, symptoms of anxiety and formal anxiety disorders are strongly correlated with depression in a wide variety of cardiac populations, as they are in the general population. Elevated symptoms of anxiety are highly prevalent in cardiac patients, including those suffering an ACS [39, 40], those with stable CAD [41], those participating in cardiac rehabilitation [42], and those hospitalized for one of several different cardiac conditions [17].

Formal anxiety disorders are frequently seen in a range of cardiac patients as well [43]; of these disorders, generalized anxiety disorder (GAD) is the most common by far. For example, GAD was concomitantly present in 38% of MDD cases in a large study of outpatients with CAD [44], and GAD was commonly comorbid with MDD among patients suffering an ACS [45].

In addition to GAD, posttraumatic stress disorder (PTSD) is common among specific populations of depressed cardiac patients, especially CABG patients and those receiving ICDs. Among patients undergoing CABG, PTSD occurs in approximately 15% of patients [14, 46], and a recent trial found that over half of post-CABG patients with PTSD had coexistent depression [46]. PTSD is at least common (18–37% in two identified studies) among patients with an ICD and is commonly comorbid with depression [47, 48]. In these patients, PTSD may stem from the cardiac event necessitating ICD placement or from firing of the device itself [49].

Anxiety disorders, especially GAD, may be associated with mortality and other adverse cardiac outcomes, independent of both traditional risk factors and depression [41, 44, 50, 51], and thus these disorders that are so often comorbid with depression should also be addressed. There is controversy regarding whether the effects of GAD and MDD on cardiac outcome are additive, with some [50], but not all [41], studies finding additive effects. Assessment for anxiety symptoms can be completed via the Hospital Anxiety and Depression Scale (which has the advantage of also containing a depression subscale), while specific screening for GAD can be completed using the Generalized Anxiety Disorder-2 [52] (GAD-2) or Generalized Anxiety Disorder-7 [53] (GAD-7) measures.

6. Association between Depression and Cardiac Outcomes

A multitude of studies over the past 15 years have confirmed that depression is associated with adverse cardiovascular outcomes, independent of traditional risk factors. In healthy
individuals, depression has been independently associated with the development and progression of CAD [54–57] and with CVD-related mortality [58]. In fact, two separate systematic quantitative reviews have found depression (diagnosed with a diagnostic interview or self-report measure) to be a significant and independent risk factor for the development of cardiac disease, with a relative risk of 1.6 (relative risk 1.64 [95% CI = 1.41–1.90] and 1.60 [95% CI 1.34–1.92], resp.) in depressed patients compared to those persons who were never depressed [56, 59].

Depressed patients with unstable CAD appear to be at even greater risk for poor cardiac outcomes. The presence of post-MI depression predicts recurrent cardiac events [60], cardiac-related death [60–63], and all-cause mortality [60, 64]. Indeed, a recent meta-analysis revealed that depressed post-MI patients have a 2.4-fold increased risk (unadjusted) for all-cause mortality (odds ratio 2.38; 95% CI = 1.76–3.22) [60]. Likewise, among patients with a wider range of unstable or angiographically validated CAD, a meta-analysis of 20 studies found depressive symptoms and MDD to be associated with mortality (Hazard ratio 1.76 [95% CI = 1.27–2.43], adjusted for other risk factors) in the two years following an event [64]. Furthermore, depressive symptoms following MI have been associated with increased hospital readmissions, particularly cardiac readmissions, and with reduced adoption of secondary prevention behaviors, including smoking cessation, physical activity, and cardiac rehabilitation [65–68].

Regarding the timing of depression onset, a 2012 meta-analysis found that depression was independently predictive of mortality and cardiac morbidity after an ACS, regardless of whether the depression was present prior to or after the onset of cardiac illness; however, first-onset depression within 30 days of an acute cardiac event was potentially more strongly linked to morbidity and mortality [69]. Of note, following an acute cardiac event, prior history of depression, without current depression, was not associated with adverse outcomes [69].

Depression also appears to substantially impact cardiovascular outcomes in patients with other forms of CVD. Clinically significant depression increases the risk of incident HF, especially in those already at increased risk for its development; in patients with established HF, it is also related to increased health care utilization, more frequent hospitalizations, and a 2-fold increase in mortality risk [12, 70]. Increased depressive symptoms are also linked to recurrence of AF in patients following cardioversion [71] and with cardiovascular mortality in patients with comorbid AF and HF [72].

In patients undergoing CABG, depression has been associated with longer hospitalization [73], poorer functional outcomes [74, 75], more perioperative complications [73], worse health-related quality of life (HRQoL) [76], progression of atherosclerotic disease [77], higher rates of rehospitalization [75], and mortality [4, 78, 79]. Finally, depression has been associated with mortality, independent of covariates, in patients with an ICD [80].

Several studies have evaluated the characteristics of psychiatric illness and its treatment that may contribute to poor cardiac outcomes in depressed cardiac patients. Nonresponse to treatment for depression, for instance, appears to put depressed post-ACS patients at greater risk for recurrent cardiac events [81] and for all-cause mortality [82]. Poor outcomes may be exacerbated by the presence of cooccurring anxiety, which is independently associated with recurrent cardiac events and mortality [83] and which has been linked with poor response to treatment for depression [84–86]. Other patients who appear to be at particularly high risk for poor outcomes include those with prominent anhedonia (the inability to experience pleasure) [87–89] and those with type D personality (a personality structure characterized by negative affectivity and social inhibition) [19], though the latter association is controversial [90].

Thus, not only is depression common and persistent in patients with CVD, but it also may have a negative impact on multiple aspects of the course of cardiovascular illness, including physical functioning, quality of life, health care utilization, rehospitalization, and mortality.

7. Potential Mechanisms Linking Depression and Cardiac Disease (Figure 1)

If indeed depression is an independent predictor of cardiac illness, it is important to understand the physiologic and behavioral underpinnings of this association. Indeed, there are a number of mechanisms that are potentially implicated in the connection between depression and adverse cardiac outcomes.

7.1. Inflammation. The contribution of inflammation to the overall development of cardiac disease—and especially to acute cardiac events—is well documented. Inflammatory cytokines have been associated with atherosclerotic plaque formation, progression, and rupture; as such they are major contributors to the pathogenesis of CAD, unstable angina, and MI [91, 92]. Furthermore, inflammation plays a key role in the pathogenesis of certain types of HF [93, 94]. Overall, inflammatory cytokines (i.e., C-reactive protein (CRP) in CAD and interleukin-6 (IL-6) in HF) have been predictive of cardiovascular mortality and disease progression in healthy individuals [58] and in patients with CAD [95] and HF [96–98].

Depression also has been linked to increased levels of cytokines (specifically CRP, IL-1, and IL-6), both in patients with and without a history of cardiac disease [54, 99–101]. Two studies provide evidence that inflammation associated with elevated depressive symptoms or MDD is associated with the development of cardiac disease and cardiovascular mortality. In a population cohort study of 908 patients without known CVD, Kop and associates [58] found that depression predicted cardiovascular mortality; controlling for inflammatory markers reduced the association by 12.7%, suggesting that inflammation partially contributed to the effects of depression on cardiovascular mortality. Similarly, in a study of 559 women with suspected cardiac ischemia,
Depression in cardiac patients

- Reduced adherence to:
  - Low-fat diet
  - Physical activity
  - Smoking cessation
  - Medication
  - Poor cardiac rehab attendance

- Elevated platelet activity (mediated by serotonin)
- Increased inflammation
- HPA axis dysfunction
- Decreased heart rate variability
- Elevated catecholamines
- Endothelial dysfunction
- Low BDNF

BDNF = brain-derived neurotrophic factor; HPA = hypothalamic-pituitary-adrenal

Figure 1: Mechanisms by which depression may impact cardiac outcomes.

Vaccarino and associates found that depression predicted cardiovascular events; controlling for inflammatory factors (CRP, IL-6) reduced this association by 20%, again suggesting a small but meaningful contribution to the effects of depression on cardiac events [102].

There are at least two potential mechanisms by which inflammation, depression, and cardiovascular disease may be linked. First, neural-immune interaction may occur. In animal models of induced fatigue, levels of the inflammatory cytokine interferon alpha increase, while extracellular levels of serotonin increase in the medial prefrontal cortex. Furthermore, treatment with a serotonin (5HT-1A) receptor agonist reduces the effects of fatigue [103, 104]. Hence, in depression, reduced serotonin actions on these receptors may be linked to increased cytokines and the subsequent effects on cardiovascular outcome. Second, elevated levels of inflammatory cytokines (e.g., interferon-gamma) are associated with increased activity of an enzyme that degrades tryptophan (a serotonin precursor) to kynurenine in patients with CVD [105]. This is likely to result in lower levels of serotonin and may represent another mechanistic link that connects inflammation to depression in patients with cardiac disease.

7.2. Endothelial Dysfunction. Endothelial dysfunction has been linked to the development of ischemic CAD in patients with atherosclerosis [106]. For example, while a normal endothelium typically releases nitric oxide in response to serotonin to ensure adequate blood flow through the coronary arteries, in atherosclerotic arteries it fails to do so. This results in vasoconstriction in areas of atherosclerosis and may provide a mechanism for myocardial ischemia and coronary thrombosis [107]. Inflammation, which has been associated with CAD, also impairs endothelial nitric oxide release and may represent a mechanism explaining the finding of endothelial dysfunction in cardiac patients [108]. In addition to its role in cardiac ischemia in patients with CAD, endothelial dysfunction independently predicts mortality in patients with HF [109, 110].

Depression also has been associated with impaired endothelial function in healthy patients [111, 112], in those at risk for CVD [113], and in those with established CVD [114]. Treatment of depression with selective serotonin reuptake inhibitors (SSRIs) has led to improved endothelial function in patients with depression and established CAD, further suggesting that endothelial dysfunction may be linked to depression's effects on cardiac outcomes [115].

7.3. Increased Platelet Activity and Aggregation. Platelet adhesion, activation, and aggregation are important components of cardiac disease, and increased platelet activity may lead to coronary events on this basis. Serotonin plays a key role in platelet biology through its binding with 5-hydroxytryptamine (5-HT) receptors on platelets. In atherosclerotic arteries, as described in the previous section, serotonin leads to platelet aggregation [106, 107]. Furthermore, elevated levels of blood serotonin predict CAD and future ischemic cardiac events in patients with suspected CAD [116]. SSRIs, which theoretically deplete platelet serotonin stores by inhibiting platelet uptake of serotonin, have also been shown to decrease platelet aggregation and activity in vitro and in patients with CAD [117, 118]. Taken together, these findings lend credence to the theory that serotonin,
through its activity on platelet aggregation, is associated with myocardial ischemia and other cardiac events.

Platelet dysfunction also occurs in patients suffering from major or minor depression; depressed patients have abnormalities in whole blood and platelet serotonin levels [119], increased platelet serotonin receptor concentrations [120, 121], and abnormally low platelet serotonin transporter levels [122], suggesting that their platelets are both more sensitive to serotonin and less able to remove it from the bloodstream. Furthermore, there is evidence—albeit mixed—suggesting that the platelets of depressed patients are hyperactive [119, 123–125]. This serotonergic and platelet dysfunction could mediate the increased risk for ischemic events in these patients. At this stage, much less is known about the association between platelet hyperaggregability and other forms of CVD.

7.4. Neurohormonal and Autonomic Nervous System Dysfunction. Neurohormonal activation may play a particularly important role in the connection between depression and outcomes in HF. Levels of circulating catecholamines (e.g., epinephrine and norepinephrine) are elevated in patients with HF, especially in those with decompensated HF, and higher levels of norepinephrine have been linked to greater mortality in this illness [126, 127]. Furthermore, increases in plasma as well as cerebrospinal fluid levels of norepinephrine have been observed in patients with MDD to the extent of being capable of causing increased mortality in HF [128]. Abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis may also play a substantial role, as cortisol (and aldosterone) are independently linked with mortality in HF, and patients with depression have elevated levels of cortisol [98]. Such hypercortisolism and other HPA-related abnormalities in depression may impact medical outcomes in other cardiac illnesses, as these abnormalities are associated with the development and progression of the metabolic syndrome, a condition characterized by dyslipidemia, truncal obesity, and insulin resistance and linked to cardiac morbidity and mortality.

Beyond elevated levels of circulating catecholamines and cortisol, other abnormalities in the autonomic nervous system may also contribute to the relationship between depression and cardiac disease. Since the heart is innervated by both the sympathetic and parasympathetic nervous systems, the interplay between these two opposing forces helps the heart make changes in response to stressors. Patients with a history of ischemic heart disease or HF typically exhibit a pattern of increased sympathetic and decreased parasympathetic activity; this is manifested by decreased baroreflex sensitivity and decreased heart rate variability (HRV) [129]. This pattern of autonomic dysfunction has been associated with increased mortality in patients with HF [129] and a history of MI [129–131] and with increased rates of recurrent AF after cardioversion [71]. In animal studies, such a pattern of autonomic dysfunction was associated with increased rates of ventricular fibrillation during recurrent ischemic episodes [132] and may represent a mechanism by which autonomic dysfunction leads to increased morbidity and mortality in cardiac patients.

Depressed patients (with and without cardiac disease) also have reduced HRV [133–135], suggestive of the same imbalance between sympathetic and parasympathetic nervous systems described previously. This reduction appears to be linearly associated with depression severity, with more severe depression resulting in greater reductions in HRV [133]. Furthermore, patients with both CAD and depression have greater decreases in HRV compared to patients with depression or CAD alone, suggesting that the effects of depression and CAD on HRV are additive [135]. This increased autonomic dysfunction in depressed patients may therefore lead to worse cardiac outcomes in patients with cooccurring HF.

7.5. Effects of Brain-Derived Neurotrophic Factor (BDNF) and Related Factors. In addition to the previous mechanisms, BDNF may also play an important role in the connection between depression and cardiac outcomes. Depression has been strongly and consistently linked to low levels of BDNF [136], and it is thought that BDNF signaling mediates the hippocampal neurogenesis that has been linked to depression recovery [137]. Indeed, SSR1 antidepressants have been associated with increased levels of BDNF [138] and with hippocampal neurogenesis [139]. BDNF also has an important role in several physiologic processes important to cardiovascular health. BDNF is expressed by endothelial cells, and it leads to angiogenesis in, and survival of, endothelial cells (primarily mediated via the phosphatidylinositol-3-kinase-Akt pathway), with increased BDNF expression during hypoxia [140]. Endothelial cells are vital to vascular health and, as noted, endothelial function is independently associated with cardiac outcomes.

Furthermore, BDNF expression is upregulated by neural signals from the heart after experimentally induced MI (interestingly, BDNF expression is increased in brain but not heart), and such expression was linked to reduced cardiomyocyte death and improved systolic function [141]. Such heart-brain connections are similarly seen with the brain sigma-1 receptor (S1R) [142]. Brain S1R appears to be associated with depression, as S1R knockout mice display depressive phenotypes [143], and S1R agonists improve such behavior [144]. A recent mouse model study showed that induced heart failure was associated with reduction in brain S1R, consistent with the investigators’ hypothesis that reduced brain S1R exacerbates heart failure [145].

Finally, BDNF may be an important mediator of the previously noted HPA axis effects on depression and cardiovascular disease. The glucocorticoid receptor interacts with the specific receptor of BDNF, TrkB, and excessive glucocorticoid interferes with BDNF signaling [146]; therefore excess glucocorticoids may be associated with adverse outcomes via BDNF-mediated effects on endothelial cells and cardiomyocytes.

7.6. Behavioral Factors. Behavioral factors are undoubtedly involved in the relationship between depression and cardiac disease. Depressed patients are less likely to engage in health-promoting behaviors, including maintenance of a healthy diet.
[66, 147], regular exercise [66, 148], adherence to medications [66, 147, 149], stress reduction [66], and completion of cardiac rehabilitation programs [150, 151] following MI. These patients also have more difficulty lowering their cholesterol following MI [152]. Medication nonadherence and lower physical fitness are associated with an increased risk of cardiovascular events in certain populations [153, 154], and this additionally suggests that the behavioral changes associated with depression may be associated with the progression of CAD and poor cardiac outcomes in patients with and without established CVD. Fortunately, in a study of hospitalized patients with a variety of cardiac conditions, those who met criteria for clinical depression during admission had improvement of adherence (to diet, exercise, and medication) if their depression improved following hospitalization [147]. This suggests that reduced adherence to key secondary prevention behaviors in depressed cardiac patients may be modifiable with treatment of the depressive symptoms.

8. Identification of Depression in Cardiac Patients

Despite the existence of effective and safe treatments for depression in cardiac patients, depression remains underrecognized and undertreated in this population [155, 156]. In one study of post-MI patients, less than 15% of depressed patients were accurately identified as such by their treatment teams, and only 11% received treatment with antidepressants [155]. Given the increased morbidity and mortality associated with depression, it is important that these patients be more consistently identified.

Routine screening of cardiac patients for depression is one potential way to improve detection of depression in this patient population. The American Heart Association recommends such screening using the 2- and 9-item Patient Health Questionnaires (PHQ-2 and PHQ-9, resp.) [23, 24, 157], two brief screening tools for depression (see Table 1 and 2). The PHQ-2 inquires about the presence and frequency of depressed mood and anhedonia, while the PHQ-9 includes questions about the nine diagnostic criteria for MDD (the first two questions of the PHQ-9 are the PHQ-2). Both screening tools are time-efficient and have the potential to be integrated into standard inpatient and outpatient evaluations. Furthermore, elevated scores on these scales have prognostic value; for example, positive screens using this two-step method have been independently associated with subsequent cardiac events in outpatients with CAD [158], and a positive PHQ-2 screen has been associated with subsequent mortality among patients with HF [159].

Regarding the operating characteristics of these tools in cardiac patients, a large study of outpatients with CAD found that the PHQ-2 (with a cutoff score of 2) had sensitivity of 82%, specificity of 79%, positive predictive value of 52%, and negative predictive value of 94% (using a contemporaneous diagnostic interview for MDD as the gold standard), making it a reasonably good screening tool in this cohort, especially given its substantial brevity and excellent ability to exclude MDD [160]. In the same cohort, PHQ-9 (using the standard cutoff score of 10) had sensitivity of 54%, specificity of 90%, positive predictive value of 61%, and negative predictive value of 88% [160]. The recommended two-step screening approach using both items did not appear to be superior to using either tool alone for screening [160]. However, a related analysis from the same study found that use of the two-step screening with PHQ-2 followed by PHQ-9 enabled nearly half of the sample to avoid undergoing the full PHQ-9 scale with few patients with "true" depression missed as a result [158].

Clinical implementation of routine, universal screening with the PHQ-2 or PHQ-9 has had some success but overall mixed results. One study of this two-step screening method found relatively high rates of completion and high staff satisfaction among patients hospitalized on inpatient cardiac units. However, in this case, the PHQ-2 screening was performed by clinical nurses as part of routine care, while the follow-up PHQ-9 was performed by a study social worker [161]. A more complete clinical implementation of the two-step screening resulted in substantial detection of depression in screened patients but only modestly improved overall recognition of depression due to a significant minority of patients who did not get screened; clinical staff reported preference for a single-stage screen instead [162]. A different approach to screening—one-yearly screening with the PHQ-9—at a large veterans affairs medical center—was associated with low rates of depression detection in cardiac patients compared to prior studies, and reliance on such archival screening may miss patients with newer-onset depression in the setting of cardiac events [25].

However, the question of whether to screen at all is a vital one. There has been much controversy about the AHA recommendations, in large part because there is no evidence that routine screening alone for depression, whether in the general population or in cardiac patients, improves patient outcomes. Critics of universal screening have, therefore, suggested that the recommendations of the AHA be reconsidered [6, 163]. Specific concerns have included potential misdiagnosis of patients with screening tools if patients with positive screens do not undergo confirmatory psychiatric interviews, unnecessary stigma for patients who may be misdiagnosed, and lack of evidence regarding the cost-effectiveness of screening programs [163].

### Table 1: Patient Health Questionnaire 2 (PHQ-2) [23]^

<table>
<thead>
<tr>
<th>Over the past two weeks, how often have you:</th>
<th>Not at all</th>
<th>Several days</th>
<th>More than half the days</th>
<th>Nearly every day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lost interest or had little pleasure in doing things</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Felt down, depressed, or hopeless</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

^Total score = sum of two items.

PHQ-2 score ≥ 3 is suggestive of elevated symptoms of depression. The PHQ-2 was developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke, and colleagues, with an educational grant from Pfizer Inc. PHQ2 Copyright © Pfizer Inc. All rights are reserved.
Table 2: Patient Health Questionnaire 9 (PHQ-9) [24].

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at all</th>
<th>Several days</th>
<th>More than half the days</th>
<th>Nearly every day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Little interest or pleasure in doing things</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Feeling down, depressed, or hopeless</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Trouble falling or staying asleep or sleeping too much</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Feeling tired or having little energy</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Poor appetite or overeating</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Feeling bad about yourself or that you are a failure or have let yourself or your family down</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Trouble concentrating on things, such as reading the newspaper or watching television</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Moving or speaking so slowly that other people could have noticed. Or the opposite—being so fidgety or restless that you have been moving around a lot more than usual</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Thoughts that you would be better off dead or of hurting yourself in some way</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?

<table>
<thead>
<tr>
<th>Difficulty Level</th>
<th>Not difficult at all</th>
<th>Somewhat difficult</th>
<th>Very difficult</th>
<th>Extremely difficult</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

Total score = sum of 9 items.

The PHQ-9 was developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke, and colleagues, with an educational grant from Pfizer Inc. PHQ9 Copyright © Pfizer Inc. All rights are reserved.

In contrast, when depression screening is paired with a management protocol or system of care (e.g., a care management program) to treat depression in persons with cardiovascular disease, there has been consistent evidence for improved patient outcomes (including, in some studies, improved adherence, reduced cardiac symptoms, reduced cardiac events and improved blood pressure and lipids) [164–167]. Thus, some proponents of universal screening suggest that systematic screening should be performed when there is an available and consistent resource for treatment available for patients who screen positive, such as collaborative care programs [168]. Such a policy would ensure that positive-screen patients would receive a more thorough depression evaluation and, if depression were diagnosed, would be able to obtain longitudinal treatment.

9. Clinical Recommendations Regarding Assessment

Screening. Where does this leave clinicians in the assessment of depression in cardiac patients? First, we agree with the assertion that depression screening should only be performed if there is a clear path to the patient getting treatment. This may take several forms: a systematic care management program, a trusted psychiatric colleague who can reliably follow the patient, or treatment directly from the primary medical team if they feel comfortable managing depression. Without the existence of such treatment options, systematic depression screening requires valuable resources (e.g., physician and nurse time) without clear benefit and may identify a new and important condition without offering adequate treatment.

When performing screening, as noted, one-time screening with the PHQ-9 appears ineffective and inefficient, while two-stage screening with the PHQ-2 followed by the PHQ-9 appears to allow for most nondepressed patients to end the screening process after only two questions while using all nine DSM-IV criteria to assess positive PHQ-2 patients. In our opinion, an approach that uses single-step screening with the PHQ-9 but halts screening with negative responses to the first two items—the items that compose the PHQ-2—may find the best balance.

Diagnosis. In patients who screen positive, how does one make a diagnosis of depression? Significant controversy exists regarding the diagnosis of depression in cardiac patients. This is especially true in patients who have had acute cardiac events. These patients may have significant anxiety and transiently depressed mood immediately following the event but may not develop MDD. Furthermore, symptoms related to the cardiac event (e.g., fatigue, poor concentration, poor appetite) may overlap significantly with the clinical symptoms of depression. As a result, some have argued for lengthening the amount of time needed for a depressive episode to be identified in patients with acute cardiac events, or for excluding somatic symptoms that could be attributed to cardiac disease.

Despite these concerns, we would recommend continuing to use the DSM-IV criteria (including the 2-week duration criterion) for the diagnosis of depression, even in patients who have had an acute cardiac event. While one could argue for waiting longer than 2 weeks in post-ACS or post-CABG patients, the toxic effect of depression on cardiac health is relatively clear, and there is some suggestion
from a recent meta-analysis that depression within 30 days of ACS (especially if it is new-onset depression) is more strongly associated with mortality and cardiac morbidity than premorbid depression or depression diagnosed over the first year [69].

Furthermore, using the DSM-IV criteria for MDD requires either loss of pleasure or depressed mood most of the day, nearly every day, for at least 2 weeks, and patients who meet this criterion, in addition to meeting other criteria (which may include somatic symptoms) in our mind, are very likely to have MDD, even in the face of cardiac illness.

While beyond the scope of this review, safe and effective medication (e.g., sertraline, which is the agent most studied in patients with acute cardiac illness [169, 170]) and psychotherapeutic (e.g., cognitive behavioral therapy, successfully used in patients with substantial cardiac illness [171, 172]) treatments are available for cardiac patients with MDD. Therefore, patients who meet full criteria for MDD should be treated, whether cardiac events are recent or remote. We hope that systematic screening and treatment of depression in patients with CVD can lead to improved psychiatric and medical outcomes in this high-risk population.

References


